Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2025)

Arcturus Therapeutics Holdings' Net Cash Flow history spans 8 years, with the latest figure at -$4.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 2867.33% year-over-year to -$4.5 million; the TTM value through Dec 2025 reached -$61.1 million, down 11.17%, while the annual FY2025 figure was -$61.1 million, 11.17% down from the prior year.
  • Net Cash Flow reached -$4.5 million in Q4 2025 per ARCT's latest filing, up from -$16.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $154.2 million in Q4 2022 to a low of -$63.9 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$11.5 million, with a median of -$20.1 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: soared 455.47% in 2022, then plummeted 2867.33% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$43.4 million in 2021, then skyrocketed by 455.47% to $154.2 million in 2022, then tumbled by 113.07% to -$20.2 million in 2023, then skyrocketed by 99.26% to -$150000.0 in 2024, then tumbled by 2867.33% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Net Cash Flow are -$4.5 million (Q4 2025), -$16.1 million (Q3 2025), and -$20.5 million (Q2 2025).